What are the recommended dosing regimens for Vraylar (cariprazine) for schizophrenia, bipolar I manic episodes, bipolar I depressive episodes, and major depressive disorder, including dose adjustments for elderly patients and hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vraylar (Cariprazine) Dosing

Vraylar dosing varies by indication, with starting doses ranging from 0.5-1.5 mg daily and maximum doses of 3-6 mg daily depending on the condition being treated. 1

Dosing by Indication

Schizophrenia

Adults:

  • Starting dose: 1.5 mg once daily
  • Titration: May increase to 3 mg on Day 2, then adjust in 1.5 mg or 3 mg increments based on response
  • Recommended range: 1.5-6 mg daily
  • Maximum dose: 6 mg daily 1

Pediatric Patients (13-17 years):

  • Starting dose: 0.5 mg once daily
  • Titration: Increase to 1.5 mg on Day 3, may increase to 3 mg on Day 5, and to 4.5 mg on Day 8
  • Recommended range: 1.5-4.5 mg daily
  • Maximum dose: 4.5 mg daily 1

Bipolar I Disorder - Manic or Mixed Episodes

Adults:

  • Starting dose: 1.5 mg once daily
  • Titration: Increase to 3 mg on Day 2, then adjust in 1.5 mg or 3 mg increments
  • Recommended range: 3-6 mg daily
  • Maximum dose: 6 mg daily 1

Pediatric Patients (10-17 years):

  • Starting dose: 0.5 mg once daily
  • Titration: Increase to 1.5 mg on Day 3, then to 3 mg on Day 5, may increase to 4.5 mg on Day 8
  • Recommended dose: 3 mg or 4.5 mg daily
  • Maximum dose: 4.5 mg daily 1

Bipolar I Disorder - Depressive Episodes

Adults only:

  • Starting dose: 1.5 mg once daily
  • Titration: May increase to 3 mg on Day 15 based on response
  • Maximum dose: 3 mg daily 1

Major Depressive Disorder (Adjunctive Therapy)

Adults only:

  • Starting dose: 1.5 mg once daily
  • Titration: May increase to 3 mg on Day 15 based on response
  • Maximum dose: 3 mg daily
  • Important: Titration intervals less than 14 days resulted in higher adverse reaction rates 1

Special Populations

Elderly Patients

Dose reductions are recommended for elderly patients, though specific dosing is not provided in the FDA label. The evidence suggests using lower starting doses and slower titration in geriatric patients, consistent with general antipsychotic prescribing principles 1.

Hepatic Impairment

The FDA label does not provide specific dosing adjustments for hepatic impairment. However, cariprazine should not be given to patients with severe hepatic disease 2. General principles suggest dose reduction may be warranted, similar to other antipsychotics 3.

Renal Impairment

Cariprazine should not be given to patients with severe renal disease 2. No specific dose adjustments are provided for mild to moderate renal impairment in the FDA label 1.

Drug Interactions Requiring Dose Adjustment

Strong CYP3A4 Inhibitors

When initiating Vraylar while taking a strong CYP3A4 inhibitor:

  • Schizophrenia/Bipolar Mania: Start at 0.5 mg daily; may increase to 0.75 mg daily if needed
  • Bipolar Depression/MDD adjunctive: 0.5 mg daily 1

When adding a strong CYP3A4 inhibitor to stable Vraylar:

  • If on 1.5 mg or 3 mg daily → reduce to 0.5 mg daily
  • If on 4.5 mg or 6 mg daily → reduce to 0.75 mg daily 1

Moderate CYP3A4 Inhibitors

When initiating Vraylar while taking a moderate CYP3A4 inhibitor:

  • Schizophrenia/Bipolar Mania: Start at 0.75 mg daily; may increase to 1.5 mg daily if needed
  • Bipolar Depression/MDD adjunctive: 0.75 mg daily 1

When adding a moderate CYP3A4 inhibitor to stable Vraylar:

  • If on 1.5 mg or 3 mg daily → reduce to 0.75 mg daily
  • If on 4.5 mg or 6 mg daily → reduce to 1.5 mg daily 1

CYP3A4 Inducers

Concomitant use of Vraylar with CYP3A4 inducers is not recommended as this combination has not been evaluated 1.

Critical Prescribing Considerations

Long Half-Life Implications

Cariprazine has a half-life of 2-4 days, with its active metabolite (didesmethyl-cariprazine) having a terminal half-life of 1-3 weeks 1, 4, 5. This means:

  • Changes in dose will not be fully reflected in plasma for several weeks
  • Monitor patients for adverse reactions and treatment response for several weeks after starting or changing doses
  • Effects may persist for weeks after discontinuation 1

Administration

  • Once daily dosing
  • Can be taken with or without food 1
  • Available in capsule strengths: 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg 1

Common Pitfalls

  1. Titrating too quickly: The long half-life means full effects take weeks to manifest. Rapid titration increases adverse reaction risk without corresponding benefit 1

  2. Exceeding maximum doses: Doses above 6 mg daily in schizophrenia and bipolar mania do not provide additional benefit but increase dose-related adverse reactions 1

  3. Forgetting drug interactions: Failure to adjust dose with CYP3A4 inhibitors can lead to excessive drug exposure 1

  4. Inadequate monitoring period: Given the long half-life, assess response over weeks, not days 1

References

2
Research

Cariprazine for Schizophrenia and Bipolar Disorder.

Innovations in clinical neuroscience, 2016

Related Questions

What is the recommended starting dose of cariprazine (Vraylar) for bipolar I disorder, and should it be taken with food?
What is the recommended dosing regimen for cariprazine (Vraylar) in adult patients with schizophrenia, bipolar I mania, or bipolar I depression, including dose adjustments for patients aged 65 years or older, hepatic impairment, and renal impairment?
What is the appropriate management for a patient who has been on Vraylar (cariprazine) 1.5 mg daily for three months?
Can an adult start Vraylar (cariprazine) at 3 mg daily?
Can I start this bipolar I patient with a recent lithium overdose and dangerous impulsivity on Vraylar (cariprazine) 1.5 mg for three days then increase to 3 mg instead of Depakote (valproate) because Depakote requires laboratory monitoring for acute mania?
When should pulmonary embolism be suspected and what constitutes a not‑high pre‑test probability?
How is the Wells score calculated to estimate the pre‑test probability of pulmonary embolism?
What is the appropriate management for an 18-year-old patient who presents with left‑ear cerumen impaction causing a sensation of blockage and right‑ear excess cerumen, without pain, fever, or signs of infection?
For a patient with chronic obstructive pulmonary disease who is at risk for renal impairment and osteoporosis, should tenofovir alafenamide (TAF) be preferred over tenofovir disoproxil fumarate (TDF) for hepatitis B therapy?
What is the recommended treatment for a patient with BCOR, EZH2, and SF3B1 mutations and 48% bone marrow blasts?
Which vaccines should a 5-year-old child receive if he has only received three doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine and two doses of inactivated poliovirus (IPV) vaccine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.